CTRI/2020/07/026630
Recruiting
Phase 2
Phase II, open label, randomized controlled trial to evaluate safety and efficacy of ACT 12 tablet and ACT 13 dry syrup as an immunomodulator in adult Covid 19 positive patients
Mr Ghanshyam Goti0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Sponsor
- Mr Ghanshyam Goti
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients admitted with RT\-PCR confirmed COVID\-19 illness
- •Age more than 18 \& less than 65 years of either sex
- •Mild to Moderately Covid 19 disease (NEWS score less than or equal to 8\)
- •Signed informed consent must be obtained and documented according to national/local regulations
Exclusion Criteria
- •Pregnant women
- •Breastfeeding women
- •Requiring ICU admission at screening
- •Patients above 65 years of age and below 18 Years
- •Past History of MI, Epileptic episodes
- •Any other co\-morbidity (uncontrolled diabetes, severe hypertension from subject history) which
- •is at critical stage at screening
- •Any other condition by which subject proves unfit from investigator perspective
- •Not giving consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Clinical trial of ShatPlus as an immunomodulator in adult Covid 19 positive patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/06/025999BVG Life Sciences Ltd
Completed
Phase 2
Evaluate Safety and Efficacy of RV Forte Capsule as an immunomodulator in adult Covid 19 positive patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/10/028568RV New Vision Healthcare Pvt Ltd60
Not yet recruiting
Phase 2
Clinical trial of herbal supplement as an immunomodulator in adult Covid 19 positive patients.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/06/026187Mr Ghanshyam Goti
Active, not recruiting
Phase 1
A randomized clinical study to investigate the efficiency of a novel anti-cancer medication against neuroblastoma in children, adolescent and young adults in whom the tumor relapsed or was refractory to standard careRelapsed or refractory high risk neuroblastomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-004062-15-DEniversity Hospital of Regensburg114
Active, not recruiting
Phase 1
A randomized clinical study to investigate the efficiency of a novel anti-cancer medication against neuroblastoma in children, adolescent and young adults in whom the tumor relapsed or was refractory to standard care.Relapsed or refractory high risk neuroblastomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-004062-15-ATniversity Hospital of Regensburg114